Please use this identifier to cite or link to this item: http://www.repositorio.ufc.br/handle/riufc/45554
Title in Portuguese: The design of novel metronidazole benzoate structures: exploring stoichiometric diversity
Author: Oliveira, Yara Santiago de
Costa, Wendell Saraiva
Borges, Poliana Ferreira
Santana, Maria Silmara Alves de
Ayala, Alejandro Pedro
Keywords: Metronidazol
Metronidazole
Issue Date: 2019
Citation: OLIVEIRA, Yara Santiago de et al. The design of novel metronidazole benzoate structures: exploring stoichiometric diversity. Acta Cryst., C75, p. 483–495, 2019.
Abstract: The use of supramolecular synthons as a strategy to control crystalline structure is a crucial factor in developing new solid forms with physicochemical properties optimized by design. However, to achieve this objective, it is necessary to understand the intermolecular interactions in the context of crystal packing. The feasibility of a given synthon depends on its flexibility to combine the drug with a variety of coformers. In the present work, the imidazole–hydroxy synthon is investigated using as the target molecule benzoylmetronidazole [BZMD; systematic name 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl benzoate], whose imidazole group seems to be a suitable acceptor for hydrogen bonds. Thus, coformers with carboxylic acid and phenol groups were chosen. According to the availability of binding sites presented in the coformer, and considering the proposed synthon and hydrogen-bond complementarity as major factors, different drug–coformer stoichiometric ratios were explored (1:1, 2:1 and 3:1). Thirteen new solid forms (two salts and eleven cocrystals) were produced, namely BZMD–benzoic acid (1/1), C13H13N3O4 C7H6O2, BZMD– -naphthol (1/1), C13H13N3O4 C10H8O, BZMD–4-methoxybenzoic acid (1/1), C13H13N3O4 C8H8O3, BZMD–3,5-dinitrobenzoic acid (1/1), C13H13N3O4 C7H4N2O6, BZMD–3-aminobenzoic acid (1/1), C13H13N3O4 C7H7NO2, BZMD–salicylic acid (1/1), C13H13N3O4 C7H6O3, BZMD–maleic acid (1/1) {as the salt 1-[2-(benzoyloxy)- ethyl]-2-methyl-5-nitro-1H-imidazol-3-ium 3-carboxyprop-2-enoate}, C13H14- N3O4 + C4H3O4 , BZMD–isophthalic acid (1/1), C13H13N3O4 C8H6O4, BZMD– resorcinol (2/1), 2C13H13N3O4 C6H6O2, BZMD–fumaric acid (2/1), C13H13N3O4 0.5C4H4O4, BZMD–malonic acid (2/1), 2C13H13N3O4 C3H2O4, BZMD–2,6-dihydroxybenzoic acid (1/1) {as the salt 1-[2-(benzoyloxy)ethyl]-2- methyl-5-nitro-1H-imidazol-3-ium 2,6-dihydroxybenzoate}, C13H14N3O4 + C7H5O4 , and BZMD–3,5-dihydroxybenzoic acid (3/1), 3C13H13N3O4 C7H6O4, and their crystalline structures elucidated, confirming the robustness of the selected synthon.
URI: http://www.repositorio.ufc.br/handle/riufc/45554
metadata.dc.type: Artigo de Periódico
ISSN: 2053-2296
Appears in Collections:DFAR - Artigos publicados em revistas científicas

Files in This Item:
File Description SizeFormat 
2019_art_ysoliveira.pdf2,39 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.